Monopost (Latanoprost)

Latanoprost activates prostaglandin F (FP) receptors in the eye, increasing uveoscleral outflow of aqueous humor. This enhanced drainage reduces intra‑ocular pressure, which is the primary therapeutic goal in glaucoma management.

The prescribed dose of Monopost is determined by the treating ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but exact dosing must follow the clinician’s instructions.

Safety data for latanoprost in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks with their healthcare provider before using Monopost.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Monopost (latanoprost) is a first‑line prostaglandin analog, generally offering once‑daily dosing and strong intra‑ocular pressure reduction. Compared with beta‑blocker eye drops, it often provides greater pressure‑lowering efficacy with a different side‑effect profile, making it a preferred option for many patients.

Monopost should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from light and moisture, and discard any solution that appears discolored or contaminated.

Monopost is applied as a single drop to the conjunctival sac of the affected eye(s) once daily, preferably in the evening. Patients should wash their hands before use, avoid touching the tip of the bottle to the eye or any surface, and close the eyelid gently after instillation.

Serious risks include severe ocular inflammation (uveitis), allergic reactions such as swelling or rash, sudden loss of vision, and corneal edema. Any abrupt changes in vision or eye discomfort should prompt immediate medical evaluation.

Monopost is contraindicated in patients with active ocular infections, known hypersensitivity to latanoprost or any component of the formulation, and should be used with caution in individuals with a history of intra‑ocular inflammation or severe ocular surface disease.